Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study

被引：2

作者：

Van Cutsem, E. ^{[1
]}

Yoshino, T. ^{[2
]}

Lenz, H-J. ^{[3
]}

Lonardi, S. ^{[4
]}

Falcone, A. ^{[5
]}

Limon, M. L. ^{[6
]}

Saunders, M. P. ^{[7
]}

Sobrero, A. ^{[8
]}

Maiello, E. ^{[9
]}

Park, Y. S. ^{[10
]}

Ferreiro Monteagudo, R. ^{[11
]}

Hong, Y. S. ^{[12
]}

Tomasek, J. ^{[13
]}

Taniguchi, H. ^{[14
]}

Ciardiello, F. ^{[15
]}

Hocke, J. ^{[16
]}

Oum'hamed, Z. ^{[17
]}

Vlassak, S. ^{[18
]}

Studeny, M. ^{[19
]}

Tabernero, J. ^{[20
]}

机构：

[1] Univ Hosp Leuven, Digest Oncol, Campus Gasthuisberg, Leuven, Belgium

[2] Natl Canc Ctr Hosp East, Dept GI Oncol, Kashiwa, Chiba, Japan

[3] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Med Oncol, Los Angeles, CA USA

[4] Ist Oncol Veneto IRCCS, Oncol Med 1, Padua, Italy

[5] Azienda Osped Univ S Chiara, Oncol Med, Pisa, Italy

[6] Hosp Univ Virgen del Rocio, Med Oncol, Seville, Spain

[7] Christie NHS Fdn Trust, Clin Oncol, Manchester, Lancs, England

[8] Osped San Martino Genova, Dept Med Oncol, Genoa, Italy

[9] Osped Casa Sollievo Sofferenza, Oncohematol, San Giovanni Rotondo, Italy

[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Med, Seoul, South Korea

[11] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain

[12] Univ Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South Korea

[13] InVentiv Hlth, Med Commun, London, England

[14] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[15] AOU SUN, Med Oncol, Naples, Italy

[16] Boehringer Ingelheim Pharma GmbH & Co KG, Stat, Tubingen, Germany

[17] Boehringer Ingelheim BV France SAS, Clin Trials, Reims, France

[18] SCS Boehringer Ingelheim Comm V, Med Affairs, Brussels, Belgium

[19] Boehringer Ingelheim GmbH & Co KG, Div Med, Clin Dev Dept, Vienna, Austria

[20] Vall dHebron Univ Hosp, Inst Oncol, Oncol Med, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw435.12

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA20_PR

引用

页数：1

共 50 条

[1] LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
Lenz, Heinz-Josef
Tabernero, Josep
Yoshino, Takayuki
Oum'Hamed, Zohra
Vlassak, Soetkin
Sassi, Mouna
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment
Lenz, Heinz-Josef
Yoshino, Takayuki
Argiles, Guillem
Iveson, Timothy
Sastre, Javier
Harrison, Mark
Lim, Howard John
Tebbutt, Niall C.
Peeters, Marc
Satoh, Taroh
Dittrich, Christian
Sassi, Mouna
Loembe, Arsene-Bienvenu
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[3] LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
Lenz, Heinz-Josef
Tabernero, Josep
Yoshino, Takayuki
Oum'Hamed, Zohra
Vlassak, Soetkin
Sassi, Mouna
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[4] Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study
Lenz, Heinz-Josef
Tabernero, Josep
Yoshino, Takayuki
Lonardi, Sara
Falcone, Alfredo
Miron, Maria Luisa Limon
Saunders, Mark P.
Sobrero, Alberto F.
Park, Young Suk
Monteagudo, Reyes Ferreiro
Hong, Yong Sang
Tomasek, Jiri
Taniguchi, Hiroya
Ciardiello, Fortunato
Sassi, Mouna
Peil, Barbara
Hastedt, Claudia
Studeny, Matus
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[5] Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment
Van Cutsem, Eric
Yoshino, Takayuki
Hocke, Julia
Oum'Hamed, Zohra
Studeny, Matus
Tabernero, Josep
CLINICAL COLORECTAL CANCER, 2016, 15 (01) : 91 - 94
[6] Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
Ciuleanu, T. E.
Brodowicz, T.
Belani, C. P.
Kim, J.
Krzakowski, M.
Laack, E.
Wu, Y.
Peterson, P.
Adachi, S.
Zielinski, C. C.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[7] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies
Hofheinz, R.
Grothey, A.
Sobrero, A. F.
Siena, S.
Falcone, A.
Ychou, M.
Lenz, H. -J
Yoshino, T.
Cihon, F.
Strauss, U. P.
Van Cutsem, E.
ONKOLOGIE, 2012, 35 : 255 - 255
[8] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.
Grothey, Axel
Sobrero, Alberto F.
Siena, Salvatore
Falcone, Alfredo
Ychou, Marc
Lenz, Heinz-Josef
Yoshino, Takayuki
Cihon, Frank
Wagner, Andrea
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[9] LUME-Colon 1: a randomized phase III study of nintedanib vs placebo in patients with advanced colorectal cancer
Yoshino, Takayuki
Tabernero, Josep
Oum'Hamed, Zohra
Studeny, Matus
Sassi, Mouna
Lenz, Heinz-Josef
Van Cutsem, Eric
ANNALS OF ONCOLOGY, 2015, 26 : 130 - 130
[10] The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).
Jonker, Derek J.
Nott, Louise M.
Yoshino, Takayuki
Li, Chiang
Gill, Shariene
Shapiro, Jeremy David
Ohtsu, Atsushl
Zalcberg, John Raymond
Vickers, Michael M.
Slims, John
Wei, Alice Chia-Chi
Mittmann, Nicole
Magoski, Nadine M.
Murray, Yvonne
Tsobanis, Eric
Tu, Dongsheng
Kerstein, David
O'Callaghan, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →